Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company focused on discovering and developing medicines for a range of indications, reported second-quarter business highlights, spotlighting progress for ORX750, an oral selective orexin-2 receptor (OX2R) agonist in development for narcolepsy and other sleep disorders.
“This is an exciting time for Centessa as we continue to execute across our portfolio with the goal of bringing transformative medicines to patients with unmet needs,” says Saurabh Saha, MD, PhD, CEO of Centessa, in a release.
In parallel with progress on its two clinical programs, one for the treatment of hemophilia B and another for solid tumors, the company is advancing ORX750, its first OX2R agonist development candidate, through Investigational New Drug-enabling studies for the treatment of narcolepsy.
The company plans to share preclinical data on ORX750 at World Sleep 2023 taking place from Oct 20 to 25 in Rio de Janeiro, Brazil.
“We are also excited to be exploring follow-up orexin agonists for potential expansion opportunities into a range of high-value sleep disorders and broader neurological indications,” says Saha in the release. “With a team comprised of experienced and insightful scientists in the orexin field, we believe Centessa is well-positioned to play a leading role in orexin agonist development.”
Centessa has multiple earlier-stage preclinical assets including additional orexin agonists and discovery-stage programs. Where applicable, the company plans to provide updates on preclinical programs as they advance toward clinical studies, according to a release from Centessa.